Meeting
2024 ASCO Genitourinary Cancers Symposium
A multicohort phase 2 trial of ADT, docetaxel plus nivolumab in patients with de novo metastatic hormone-sensitive prostate cancer enriched for inflamed tumors and DNA damage repair defects.
Authors
Xiao X. Wei
Dana-Farber Cancer Institute, Boston, MA
Xiao X. Wei , Wanling Xie , Jad Chahoud , Hamid Emamekhoo , Rana R. McKay , Catherine Handy Marshall , David Johnson Einstein , Joshua Michael Lang , Sarah Raymond , Daniel Aaron Roberts , Rajitha Sunkara , Praful Ravi , Alok Tewari , Mark Pomerantz , Fei Dong , Stephanie Siegmund , Scott J. Rodig , Kathleen L. Pfaff , Christopher Sweeney , Mary-Ellen Taplin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04126070
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS244)
DOI
10.1200/JCO.2024.42.4_suppl.TPS244
Abstract #
TPS244
Poster Bd #
Q5
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
First Author: Channing Judith Paller
Poster
2019 ASCO Annual Meeting
DNA damage repair (DDR) gene alterations as a predictive biomarker for response to platinum-containing chemotherapy in advanced biliary tract cancer (BTC).
First Author: Heejung Chae
Poster
2023 ASCO Genitourinary Cancers Symposium
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
First Author: Channing Judith Paller
Poster
2020 Genitourinary Cancers Symposium
TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).
First Author: Johann S. De Bono